180 related articles for article (PubMed ID: 32296256)
1. Fluorescent Imaging for
McMahon NP; Solanki A; Jones J; Kwon S; Chang YH; Chin K; Nederlof MA; Gray JW; Gibbs SL
Proc SPIE Int Soc Opt Eng; 2020 Feb; 11219():. PubMed ID: 32296256
[TBL] [Abstract][Full Text] [Related]
2. Signal removal methods for highly multiplexed immunofluorescent staining using antibody conjugated oligonucleotides.
McMahon N; Jones J; Eng J; Kwon S; Chang YH; Thibault G; Chin K; Nederlof M; Gray J; Gibbs SL
Proc SPIE Int Soc Opt Eng; 2019 Feb; 10881():. PubMed ID: 32280155
[TBL] [Abstract][Full Text] [Related]
3. TRIPODD: a Novel Fluorescence Imaging Platform for In Situ Quantification of Drug Distribution and Therapeutic Response.
McMahon NP; Solanki A; Wang LG; Montaño AR; Jones JA; Samkoe KS; Tichauer KM; Gibbs SL
Mol Imaging Biol; 2021 Oct; 23(5):650-664. PubMed ID: 33751366
[TBL] [Abstract][Full Text] [Related]
4. Flexible Cyclic Immunofluorescence (cyCIF) Using Oligonucleotide Barcoded Antibodies.
McMahon NP; Jones JA; Anderson AN; Dietz MS; Wong MH; Gibbs SL
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765785
[TBL] [Abstract][Full Text] [Related]
5. Intracellular paired agent imaging enables improved evaluation of tyrosine kinase inhibitor target engagement.
Solanki A; Wang L; Korber J; McMahon N; Tichauer K; Samkoe KS; Gibbs SL
Proc SPIE Int Soc Opt Eng; 2020 Feb; 11219():. PubMed ID: 32292225
[TBL] [Abstract][Full Text] [Related]
6. Oligonucleotide conjugated antibodies permit highly multiplexed immunofluorescence for future use in clinical histopathology.
McMahon NP; Jones JA; Kwon S; Chin K; Nederlof MA; Gray JW; Gibbs SL
J Biomed Opt; 2020 May; 25(5):1-18. PubMed ID: 32445299
[TBL] [Abstract][Full Text] [Related]
7. Oligonucleotide conjugated antibody strategies for cyclic immunostaining.
Jones JA; McMahon NP; Zheng T; Eng J; Chin K; Kwon S; Nederlof MA; Gray JW; Gibbs SL
Sci Rep; 2021 Dec; 11(1):23844. PubMed ID: 34903759
[TBL] [Abstract][Full Text] [Related]
8. Cyclic Immunofluorescence (CycIF), A Highly Multiplexed Method for Single-cell Imaging.
Lin JR; Fallahi-Sichani M; Chen JY; Sorger PK
Curr Protoc Chem Biol; 2016 Dec; 8(4):251-264. PubMed ID: 27925668
[TBL] [Abstract][Full Text] [Related]
9. Examining the Feasibility of Quantifying Receptor Availability Using Cross-Modality Paired-Agent Imaging.
Meng B; Sadeghipour N; Folaron MR; Strawbridge RR; Samkoe KS; Tichauer KM; Davis SC
Mol Imaging Biol; 2022 Feb; 24(1):23-30. PubMed ID: 34286423
[TBL] [Abstract][Full Text] [Related]
10. Ultra high content analyses of circulating and tumor associated hybrid cells reveal phenotypic heterogeneity.
Whalen RM; Anderson AN; Jones JA; Sims Z; Chang YH; Nederlof MA; Wong MH; Gibbs SL
Sci Rep; 2024 Mar; 14(1):7350. PubMed ID: 38538742
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous extracellular and intracellular quantification of EGFR using paired-agent imaging in an
Samkoe KS; Schultz E; Solanki A; Wang L; Korber J; Tichauer KM; Gibbs SL
Proc SPIE Int Soc Opt Eng; 2019 Feb; 10859():. PubMed ID: 32296254
[TBL] [Abstract][Full Text] [Related]
12. Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes.
Lin JR; Izar B; Wang S; Yapp C; Mei S; Shah PM; Santagata S; Sorger PK
Elife; 2018 Jul; 7():. PubMed ID: 29993362
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
14. Circulating Proteoglycan Endocan Mediates EGFR-Driven Progression of Non-Small Cell Lung Cancer.
Yang YC; Pan KF; Lee WJ; Chang JH; Tan P; Gu CC; Chang WM; Yang SF; Hsiao M; Hua KT; Chien MH
Cancer Res; 2020 Aug; 80(16):3292-3304. PubMed ID: 32561533
[TBL] [Abstract][Full Text] [Related]
15. Resisting Resistance: Targeted Therapies in Lung Cancer.
Lin JJ; Shaw AT
Trends Cancer; 2016 Jul; 2(7):350-364. PubMed ID: 27819059
[TBL] [Abstract][Full Text] [Related]
16. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
[TBL] [Abstract][Full Text] [Related]
17. Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops.
von Manstein V; Yang CM; Richter D; Delis N; Vafaizadeh V; Groner B
Curr Signal Transduct Ther; 2013 Dec; 8(3):193-202. PubMed ID: 25045345
[TBL] [Abstract][Full Text] [Related]
18. Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Recondo G; Bahcall M; Spurr LF; Che J; Ricciuti B; Leonardi GC; Lo YC; Li YY; Lamberti G; Nguyen T; Milan MSD; Venkatraman D; Umeton R; Paweletz CP; Albayrak A; Cherniack AD; Price KS; Fairclough SR; Nishino M; Sholl LM; Oxnard GR; Jänne PA; Awad MM
Clin Cancer Res; 2020 Jun; 26(11):2615-2625. PubMed ID: 32034073
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive quantification of target availability during therapy using paired-agent fluorescence tomography.
Meng B; Folaron MR; Strawbridge RR; Sadeghipour N; Samkoe KS; Tichauer K; Davis SC
Theranostics; 2020; 10(24):11230-11243. PubMed ID: 33042280
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
